Danaher Corporation DHR
At closeNov 6, 2026, 5:59 PM EST
After hours · Nov 6, 5:59 PM ET
- YTD
- +0.58%
- 1 year
- +9.29%
- Market cap
- 161.86B
- Revenue (ttm)
- 25.61B
- Profit margin
- 16.91%
- EPS (ttm)
- 6.04
- Shares out
- 702.99M
- P/E ratio
- 38.12
- Forward P/E
- 24.71
- Dividend
- 1.60 (0.71%)
- Ex-dividend date
- Sep 29, 2026
- YTD return
- +0.58%
- 1-year return
- +9.29%
- Volume
- 4.06M
- Avg volume
- 3.98M
- Open
- 222.96
- Previous close
- 226.34
- Day's range
- 222.96 – 230.66
- 52-week range
- 161.91 – 242.05
- Beta
- 0.80
- Analysts
- Strong Buy
- Price target
- 259.90 (+12.9%)
- Earnings date
- Jan 27, 2027
ALL +230.16 (+257825.39%)
Key statistics
- Enterprise value
- 181.35B
- PEG ratio
- 1.28
- Price / sales
- 6.32
- Price / book
- 3.02
- Dividend yield
- 0.71%
- Payout ratio
- 25.17%
- Revenue growth
- 8.30%
- Free cash flow
- 4.75B
- Total cash
- 5.68B
- Total debt
- 27.78B
- Return on equity
- 8.19%
- Short % of float
- 1.30%
- 50-day average
- 219.93
- 200-day average
- 200.95
Analyst view
Consensus: strong buy
- Target (low)
- 220.00
- Target (mean)
- 259.90
- Target (high)
- 310.00
- Strong buy3
- Buy17
- Hold4
- Sell0
- Strong sell0
Next earnings
Jan 27, 2027
Expected Jan 27, 2027. Consensus EPS estimate 2.48.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Jan 27, 2027 | Dec 25, 2026 | 2.49 | — | — | — |
| Oct 21, 2026 | Sep 25, 2026 | 1.92 | 2.11 | +0.19 | +9.90% |
| Jul 21, 2026 | Jun 26, 2026 | 1.85 | 1.94 | +0.09 | +4.86% |
| Apr 21, 2026 | Mar 27, 2026 | 1.94 | 2.06 | +0.12 | +6.19% |
| Jan 28, 2026 | Dec 31, 2025 | 2.16 | 2.23 | +0.07 | +3.24% |
| Oct 21, 2025 | Sep 26, 2025 | 1.72 | 1.89 | +0.17 | +9.88% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 22, 2026 | Citigroup | main | Buy | Buy |
| Oct 22, 2026 | Barclays | main | Overweight | Overweight |
| Oct 22, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 22, 2026 | TD Cowen | main | Buy | Buy |
| Oct 22, 2026 | Stifel | main | Buy | Buy |
| Oct 22, 2026 | Baird | main | Outperform | Outperform |
About Danaher Corporation
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, and aseptic fill finish; single-use hardware, consumables, and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services for diagnostic and assay development; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; bioanalytical measurement systems; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; genome sample preparation; microscopes; protein consumables; filtration products; and genomic medicines, such as custom nucleic acid products, and plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, GENEDATA, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX, and SCIEX brands. The Diagnostics segment offers clinical instruments, consumables, software, and services that hospitals, physicians' offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was incorporated in 1969 and is headquartered in Washington, the District Of Columbia.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- danaher.com
News
Danaher Companies Integrated DNA Technologies And Aldevron Jointly Launch New Research-Grade mRNA Solutions Designed For Base And Prime Editing Workflows 
Danaher Corporation $DHR Shares Newly Purchased by Associated Banc Corp 
International Assets Investment Management LLC Purchases 7,846 Shares of Danaher Corporation $DHR 
Danaher Corporation $DHR Holdings Trimmed by Bank Julius Baer & Co. Ltd Zurich 
Danaher to Present at UBS Global and Jefferies Global Healthcare Conferences 
Bill Ackman’s 20-Year Investing Rule Puts These Cash-Flow and Moat ETFs in Focus 
Billionaire Investor Adds to Danaher Stake After Cutting It Earlier This Year 
Danaher Posts First Earnings Under New CEO; Emphasizes Need For Improved Execution, Innovation 
Citigroup Maintains Buy on Danaher, Raises Price Target to $270 
Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
Your note
Sign in to keep a note on DHR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLAIR RAINER M | Chief Executive Officer | Sale | Aug 20, 2026 | 0 |
| FILLER LINDA | Director | Conversion of Exercise of derivative security | Jul 14, 2026 | 48,419 |
| GUTIERREZ-RAMOS JOSE-CARLOS | Officer | Stock Award(Grant) | Aug 3, 2026 | 32,495 |
| MCGREW MATTHEW | Officer | Stock Award(Grant) | Feb 26, 2026 | 37,063 |
| RALES MITCHELL P | Officer and Director | Stock Award(Grant) | Aug 3, 2026 | 27,509,900 |
| RALES STEVEN M | Chairman of the Board | Stock Award(Grant) | Aug 3, 2026 | 34,626,700 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 7.83% | 55,084,630 | 12.68B | Jun 29, 2026 |
| Vanguard Capital Management LLC | 5.88% | 41,377,076 | 9.53B | Jun 29, 2026 |
| FMR, LLC | 4.20% | 29,540,895 | 6.80B | Jun 29, 2026 |
| State Street Corporation | 4.04% | 28,456,019 | 6.55B | Jun 29, 2026 |
| Wellington Management Group, LLP | 2.32% | 16,316,834 | 3.76B | Jun 29, 2026 |
| Capital International Investors | 2.20% | 15,504,420 | 3.57B | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.87% | 20,222,923 | 4.66B | Jun 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 2.32% | 16,324,198 | 3.76B | Jun 29, 2026 |
| WASHINGTON MUTUAL INVESTORS FUND | 1.23% | 8,680,062 | 2.00B | Sep 29, 2026 |
| iShares Trust-iShares Core S&P 500 ETF | 1.19% | 8,337,021 | 1.92B | Sep 29, 2026 |
| Fidelity Contrafund | 1.17% | 8,247,102 | 1.90B | Sep 29, 2026 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 1.16% | 8,131,021 | 1.87B | Sep 29, 2026 |